Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Sep;63(9):1009–1014. doi: 10.1136/ard.2003.017673

A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism

E Hachulla 1, J Coghlan 1
PMCID: PMC1755145  PMID: 15308510

Full Text

The Full Text of this article is available as a PDF (88.4 KB).

Figure 1.

Figure 1

Open in a new tab

 PAH: pathogenesis occurs before clinical symptoms.22 Reproduced, with permission of Elsevier Science from Rich.22

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abu-Shakra M., Lee P. Mortality in systemic sclerosis: a comparison with the general population. J Rheumatol. 1995 Nov;22(11):2100–2102. [PubMed] [Google Scholar]
  2. Badesch D. B., Tapson V. F., McGoon M. D., Brundage B. H., Rubin L. J., Wigley F. M., Rich S., Barst R. J., Barrett P. S., Kral K. M. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000 Mar 21;132(6):425–434. doi: 10.7326/0003-4819-132-6-200003210-00002. [DOI] [PubMed] [Google Scholar]
  3. Barst Robyn J., Langleben David, Frost Adaani, Horn Evelyn M., Oudiz Ronald, Shapiro Shelley, McLaughlin Vallerie, Hill Nicholas, Tapson Victor F., Robbins Ivan M. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2003 Nov 20;169(4):441–447. doi: 10.1164/rccm.200307-957OC. [DOI] [PubMed] [Google Scholar]
  4. Battle R. W., Davitt M. A., Cooper S. M., Buckley L. M., Leib E. S., Beglin P. A., Tischler M. D. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest. 1996 Dec;110(6):1515–1519. doi: 10.1378/chest.110.6.1515. [DOI] [PubMed] [Google Scholar]
  5. British Cardiac Society Guidelines and Medical Practice Committee, and approved by the British Thoracic Society and the British Society of Rheumatology Recommendations on the management of pulmonary hypertension in clinical practice. Heart. 2001 Sep;86 (Suppl 1):I1–13. [PMC free article] [PubMed] [Google Scholar]
  6. Bryan C., Howard Y., Brennan P., Black C., Silman A. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol. 1996 Nov;35(11):1122–1126. doi: 10.1093/rheumatology/35.11.1122. [DOI] [PubMed] [Google Scholar]
  7. Channick R. N., Simonneau G., Sitbon O., Robbins I. M., Frost A., Tapson V. F., Badesch D. B., Roux S., Rainisio M., Bodin F. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001 Oct 6;358(9288):1119–1123. doi: 10.1016/S0140-6736(01)06250-X. [DOI] [PubMed] [Google Scholar]
  8. Chatterjee Kanu, De Marco Teresa, Alpert Joseph S. Pulmonary hypertension: hemodynamic diagnosis and management. Arch Intern Med. 2002 Sep 23;162(17):1925–1933. doi: 10.1001/archinte.162.17.1925. [DOI] [PubMed] [Google Scholar]
  9. Chen S. J., Chen Y. F., Meng Q. C., Durand J., Dicarlo V. S., Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol (1985) 1995 Dec;79(6):2122–2131. doi: 10.1152/jappl.1995.79.6.2122. [DOI] [PubMed] [Google Scholar]
  10. Denton C. P., Black C. M. Scleroderma and related disorders: therapeutic aspects. Baillieres Best Pract Res Clin Rheumatol. 2000 Mar;14(1):17–35. doi: 10.1053/berh.1999.0075. [DOI] [PubMed] [Google Scholar]
  11. Denton C. P., Cailes J. B., Phillips G. D., Wells A. U., Black C. M., Bois R. M. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol. 1997 Feb;36(2):239–243. doi: 10.1093/rheumatology/36.2.239. [DOI] [PubMed] [Google Scholar]
  12. Gaine S. P., Rubin L. J. Primary pulmonary hypertension. Lancet. 1998 Aug 29;352(9129):719–725. doi: 10.1016/S0140-6736(98)02111-4. [DOI] [PubMed] [Google Scholar]
  13. Galiè Nazzareno, Hinderliter Alan L., Torbicki Adam, Fourme Thierry, Simonneau Gerald, Pulido Tomas, Espinola-Zavaleta Nilda, Rocchi Guido, Manes Alessandra, Frantz Robert. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2003 Apr 16;41(8):1380–1386. doi: 10.1016/s0735-1097(03)00121-9. [DOI] [PubMed] [Google Scholar]
  14. Galiè Nazzareno, Humbert Marc, Vachiéry Jean-Luc, Vizza Carmine Dario, Kneussl Meinhard, Manes Alessandra, Sitbon Olivier, Torbicki Adam, Delcroix Marion, Naeije Robert. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002 May 1;39(9):1496–1502. doi: 10.1016/s0735-1097(02)01786-2. [DOI] [PubMed] [Google Scholar]
  15. Giaid A., Yanagisawa M., Langleben D., Michel R. P., Levy R., Shennib H., Kimura S., Masaki T., Duguid W. P., Stewart D. J. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993 Jun 17;328(24):1732–1739. doi: 10.1056/NEJM199306173282402. [DOI] [PubMed] [Google Scholar]
  16. Hoeper M. M. Pulmonary hypertension in collagen vascular disease. Eur Respir J. 2002 Mar;19(3):571–576. doi: 10.1183/09031936.02.01512001. [DOI] [PubMed] [Google Scholar]
  17. Kawut Steven M., Taichman Darren B., Archer-Chicko Christine L., Palevsky Harold I., Kimmel Stephen E. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest. 2003 Feb;123(2):344–350. doi: 10.1378/chest.123.2.344. [DOI] [PubMed] [Google Scholar]
  18. Kazzam E., Waldenström A., Hedner T., Hedner J., Caidahl K. Endothelin may be pathogenic in systemic sclerosis of the heart. Int J Cardiol. 1997 Jun 27;60(1):31–39. doi: 10.1016/s0167-5273(97)02947-1. [DOI] [PubMed] [Google Scholar]
  19. Kim Nick H. S., Rubin Lewis J. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J Cardiovasc Pharmacol Ther. 2002 Jan;7(1):9–19. doi: 10.1177/107424840200700i102. [DOI] [PubMed] [Google Scholar]
  20. Koh E. T., Lee P., Gladman D. D., Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol. 1996 Oct;35(10):989–993. doi: 10.1093/rheumatology/35.10.989. [DOI] [PubMed] [Google Scholar]
  21. Kuhn Karl P., Byrne Daniel W., Arbogast Patrick G., Doyle Thomas P., Loyd James E., Robbins Ivan M. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med. 2002 Nov 21;167(4):580–586. doi: 10.1164/rccm.200204-333OC. [DOI] [PubMed] [Google Scholar]
  22. Launay D., Hachulla E., Hatron P. Y., Michon-Pasturel U., Hebbar M., Queyrel V., Goullard L., Robin S., Rémy-Jardin M., Devulder B. Dépistage de l'hypertension artérielle pulmonaire au cours de la sclérodermie systémique: étude d'une cohorte de 67 patients. Rev Med Interne. 2001 Sep;22(9):819–829. doi: 10.1016/s0248-8663(01)00433-7. [DOI] [PubMed] [Google Scholar]
  23. LeRoy E. C., Medsger T. A., Jr Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001 Jul;28(7):1573–1576. [PubMed] [Google Scholar]
  24. Lee P., Langevitz P., Alderdice C. A., Aubrey M., Baer P. A., Baron M., Buskila D., Dutz J. P., Khostanteen I., Piper S. Mortality in systemic sclerosis (scleroderma). Q J Med. 1992 Feb;82(298):139–148. [PubMed] [Google Scholar]
  25. Maeda M., Kachi H., Takagi H., Kitajima Y. Is there circadian variation of plasma endothelin (ET-1) in patients with systemic scleroderma (SSc)? J Dermatol Sci. 1997 Nov;16(1):38–44. doi: 10.1016/s0923-1811(97)00619-1. [DOI] [PubMed] [Google Scholar]
  26. Mayes Maureen D., Lacey James V., Jr, Beebe-Dimmer Jennifer, Gillespie Brenda W., Cooper Brenda, Laing Timothy J., Schottenfeld David. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003 Aug;48(8):2246–2255. doi: 10.1002/art.11073. [DOI] [PubMed] [Google Scholar]
  27. Medsger T. A., Jr, Masi A. T. Epidemiology of systemic sclerosis (scleroderma). Ann Intern Med. 1971 May;74(5):714–721. doi: 10.7326/0003-4819-74-5-714. [DOI] [PubMed] [Google Scholar]
  28. Miyamoto S., Nagaya N., Satoh T., Kyotani S., Sakamaki F., Fujita M., Nakanishi N., Miyatake K. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):487–492. doi: 10.1164/ajrccm.161.2.9906015. [DOI] [PubMed] [Google Scholar]
  29. Mukerjee D., St George D., Coleiro B., Knight C., Denton C. P., Davar J., Black C. M., Coghlan J. G. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003 Nov;62(11):1088–1093. doi: 10.1136/ard.62.11.1088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Olschewski Horst, Simonneau Gerald, Galiè Nazzareno, Higenbottam Timothy, Naeije Robert, Rubin Lewis J., Nikkho Sylvia, Speich Rudolf, Hoeper Marius M., Behr Jürgen. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002 Aug 1;347(5):322–329. doi: 10.1056/NEJMoa020204. [DOI] [PubMed] [Google Scholar]
  31. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980 May;23(5):581–590. doi: 10.1002/art.1780230510. [DOI] [PubMed] [Google Scholar]
  32. Rich S., Kaufmann E., Levy P. S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992 Jul 9;327(2):76–81. doi: 10.1056/NEJM199207093270203. [DOI] [PubMed] [Google Scholar]
  33. Rich S. Primary pulmonary hypertension. Prog Cardiovasc Dis. 1988 Nov-Dec;31(3):205–238. doi: 10.1016/0033-0620(88)90016-3. [DOI] [PubMed] [Google Scholar]
  34. Rubin Lewis J., Badesch David B., Barst Robyn J., Galie Nazzareno, Black Carol M., Keogh Anne, Pulido Tomas, Frost Adaani, Roux Sebastien, Leconte Isabelle. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 Mar 21;346(12):896–903. doi: 10.1056/NEJMoa012212. [DOI] [PubMed] [Google Scholar]
  35. Rubin Lewis J., Roux Sébastien. Bosentan: a dual endothelin receptor antagonist. Expert Opin Investig Drugs. 2002 Jul;11(7):991–1002. doi: 10.1517/13543784.11.7.991. [DOI] [PubMed] [Google Scholar]
  36. Sanchez O., Humbert M., Sitbon O., Nunes H., Garcia G., Simonneau G. Hypertension artérielle pulmonaire associée aux connectivites. Rev Med Interne. 2002 Jan;23(1):41–54. doi: 10.1016/s0248-8663(01)00514-8. [DOI] [PubMed] [Google Scholar]
  37. Sanchez O., Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax. 1999 Mar;54(3):273–277. doi: 10.1136/thx.54.3.273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Sanchez Olivier, Nunes Hilario, Sitbon Olivier, Garcia Gilles, Simonneau Gérald, Humbert Marc. Hypertension artérielle pulmonaire associée à la sclérodermie. Ann Med Interne (Paris) 2002 Jun;153(4):250–259. [PubMed] [Google Scholar]
  39. Simeón C. P., Armadans L., Fonollosa V., Solans R., Selva A., Villar M., Lima J., Vaqué J., Vilardell M. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 2003 Jan;42(1):71–75. doi: 10.1093/rheumatology/keg033. [DOI] [PubMed] [Google Scholar]
  40. Simonneau Gerald, Barst Robyn J., Galie Nazzareno, Naeije Robert, Rich Stuart, Bourge Robert C., Keogh Anne, Oudiz Ronald, Frost Adaani, Blackburn Shelmer D. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002 Mar 15;165(6):800–804. doi: 10.1164/ajrccm.165.6.2106079. [DOI] [PubMed] [Google Scholar]
  41. Sitbon O., Humbert M., Jagot J. L., Taravella O., Fartoukh M., Parent F., Herve P., Simonneau G. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J. 1998 Aug;12(2):265–270. doi: 10.1183/09031936.98.12020265. [DOI] [PubMed] [Google Scholar]
  42. Steen V. D. Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg. 1998 Mar;17(1):48–54. doi: 10.1016/s1085-5629(98)80062-x. [DOI] [PubMed] [Google Scholar]
  43. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis. 2003 Feb;62(2):97–99. doi: 10.1136/ard.62.2.97. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Steen Virginia, Medsger Thomas A., Jr Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003 Feb;48(2):516–522. doi: 10.1002/art.10775. [DOI] [PubMed] [Google Scholar]
  45. Tilton R. G., Brock T. A., Dixon R. A. Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension. Expert Opin Investig Drugs. 2001 Jul;10(7):1291–1308. doi: 10.1517/13543784.10.7.1291. [DOI] [PubMed] [Google Scholar]
  46. Vancheeswaran R., Azam A., Black C., Dashwood M. R. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol. 1994 Jul;21(7):1268–1276. [PubMed] [Google Scholar]
  47. Vlachoyiannopoulos P. G., Dafni U. G., Pakas I., Spyropoulou-Vlachou M., Stavropoulos-Giokas C., Moutsopoulos H. M. Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. Ann Rheum Dis. 2000 May;59(5):359–367. doi: 10.1136/ard.59.5.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Yamane K. Endothelin and collagen vascular disease: a review with special reference to Raynaud's phenomenon and systemic sclerosis. Intern Med. 1994 Oct;33(10):579–582. doi: 10.2169/internalmedicine.33.579. [DOI] [PubMed] [Google Scholar]
  49. Yamane K., Miyauchi T., Suzuki N., Yuhara T., Akama T., Suzuki H., Kashiwagi H. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol. 1992 Oct;19(10):1566–1571. [PubMed] [Google Scholar]
  50. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31;332(6163):411–415. doi: 10.1038/332411a0. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES